AstraZeneca’s (AZN) “Buy” Rating Reaffirmed at Berenberg Bank

AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by equities research analysts at Berenberg Bank in a report released on Monday,Digital Look reports. They presently have a GBX 140 ($1.74) price objective on the biopharmaceutical company’s stock. Berenberg Bank’s price target would indicate a potential downside of 98.75% from the company’s current price.

Several other analysts have also recently commented on AZN. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. JPMorgan Chase & Co. restated an “overweight” rating and issued a £140 ($174.19) price objective on shares of AstraZeneca in a research report on Friday, November 22nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of GBX 7,935.67 ($98.74).

AstraZeneca Trading Down 0.1 %

Shares of AZN traded down GBX 10 ($0.12) on Monday, reaching £111.70 ($138.98). 6,044,899 shares of the company’s stock were exchanged, compared to its average volume of 46,410,563. The business has a 50 day moving average price of £105.88 and a two-hundred day moving average price of £115.38. AstraZeneca has a 12 month low of GBX 9,461 ($117.72) and a 12 month high of £133.88 ($166.58). The stock has a market capitalization of £173.13 billion, a P/E ratio of 3,546.03, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 84.97.

Insider Transactions at AstraZeneca

In other AstraZeneca news, insider Pascal Soriot purchased 20,000 shares of the business’s stock in a transaction on Thursday, November 14th. The stock was acquired at an average price of £102.03 ($126.95) per share, with a total value of £2,040,600 ($2,539,007.09). Also, insider Tony Mok acquired 1,500 shares of the company’s stock in a transaction dated Tuesday, November 19th. The stock was bought at an average cost of £126.80 ($157.77) per share, for a total transaction of £190,200 ($236,655.47). Company insiders own 0.04% of the company’s stock.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.